This company is no longer active
Tricida Past Earnings Performance
Past criteria checks 0/6
Tricida's earnings have been declining at an average annual rate of -16.8%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually.
Key information
-16.8%
Earnings growth rate
49.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Tricida enters $125M debt facility
Oct 19Tricida: Important Binary Event Coming Up
Sep 21Calculating The Intrinsic Value Of Tricida, Inc. (NASDAQ:TCDA)
Sep 14
Insider Buying: The Tricida, Inc. (NASDAQ:TCDA) CFO & Executive VP Just Bought 6.5% More Shares
Dec 14Tricida revises VALOR-CKD trial protocol, updates patent protection, shares down 14%
Dec 09Tricida's Veverimer CRL And Regulatory Updates: An Analysis
Nov 17Tricida slumps 46% on FDA feedback on veverimer proposal; launches cost-cutting initiatives
Oct 29Revenue & Expenses BreakdownBeta
How Tricida makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -134 | 32 | 92 |
| 30 Jun 22 | 0 | -148 | 37 | 99 |
| 31 Mar 22 | 0 | -153 | 37 | 102 |
| 31 Dec 21 | 0 | -177 | 38 | 115 |
| 30 Sep 21 | 0 | -181 | 38 | 105 |
| 30 Jun 21 | 0 | -219 | 58 | 121 |
| 31 Mar 21 | 0 | -244 | 77 | 130 |
| 31 Dec 20 | 0 | -265 | 90 | 147 |
| 30 Sep 20 | 0 | -268 | 99 | 162 |
| 30 Jun 20 | 0 | -235 | 83 | 151 |
| 31 Mar 20 | 0 | -213 | 63 | 151 |
| 31 Dec 19 | 0 | -177 | 46 | 133 |
| 30 Sep 19 | 0 | -146 | 34 | 115 |
| 30 Jun 19 | 0 | -131 | 26 | 108 |
| 31 Mar 19 | 0 | -120 | 21 | 100 |
| 31 Dec 18 | 0 | -103 | 18 | 86 |
| 30 Sep 18 | 0 | -96 | 15 | 81 |
| 30 Jun 18 | 0 | -77 | 14 | 63 |
| 31 Mar 18 | 0 | -60 | 12 | 47 |
| 31 Dec 17 | 0 | -41 | 11 | 36 |
Quality Earnings: TCDA.Q is currently unprofitable.
Growing Profit Margin: TCDA.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TCDA.Q is unprofitable, and losses have increased over the past 5 years at a rate of 16.8% per year.
Accelerating Growth: Unable to compare TCDA.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TCDA.Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.3%).
Return on Equity
High ROE: TCDA.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.